Lilly, Incyte: Olumiant Superior to Placebo in Scalp Hair Regrowth as Early as 24 Weeks
September 30 2021 - 7:03AM
Dow Jones News
By Colin Kellaher
Eli Lilly & Co. and Incyte Corp. on Thursday said a pair of
Phase 3 studies showed that once-daily four-milligram doses of
their arthritis drug Olumiant was superior to placebo in achieving
significant scalp hair regrowth as early as 24 weeks in adults with
severe alopecia areata.
The companies earlier this year had reported that the studies
showed significant improvements in scalp hair regrowth compared
with placebo at 36 weeks for patients taking 2- and 4-milligram
doses.
Eli Lilly said it plans to file for U.S. Food and Drug
Administration approval for Olumiant in alopecia areata by the end
of the year. There are currently no FDA-approved treatments for the
autoimmune disorder, which can cause unpredictable hair loss on the
scalp, face and other areas of the body.
Olumiant is approved in dozens of countries around the world for
adults with moderate to severe rheumatoid arthritis and for adults
with moderate to severe atopic dermatitis who are candidates for
systemic therapy. The drug is also approved for the treatment of
hospitalized patients with Covid-19 in several countries, including
Japan and Switzerland.
Indianapolis-based Eli Lilly signed an exclusive world-wide
license and collaboration agreement with Incyte, a Wilmington,
Del., biopharmaceutical company, in late 2009 to develop and
commercialize Olumiant and other compounds for inflammatory and
autoimmune diseases.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 30, 2021 06:48 ET (10:48 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jul 2023 to Jul 2024